Skip to main content
Premium Trial:

Request an Annual Quote

Emerald BioStructures, UCB Extend Deal for Drug Target Identification

NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.

The three-year extension provides the company with research funding, it said. The Bainbridge Island, Wash.-based firm also is eligible for milestone payments and royalties on future drug product revenues.

Additional financial and other details of the deal were not disclosed.

The collaboration between Emerald and UCB, a global biopharmaceutical firm based in Brussels, originally dates to 2009. Earlier this year, the firms said they had achieved a second milestone in their partnership and expanded the alliance.

Emerald is contributing its expertise in high-throughput crystallography and ligand characterization "to provide fragment screening and structural biology support for UCB's severe diseases discovery programs," it said.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.